Eli Lilly posts Q1 2026 results led by Mounjaro and Zepbound
The incretin franchise again carried the quarter, keeping attention on supply, pricing and access as competition builds.
The wire
- 01Eli Lilly reported first-quarter 2026 results with tirzepatide brands Mounjaro and Zepbound driving the performance.
- 02Lilly's incretin volumes shape what compounders, telehealth prescribers and payers can expect on availability and net pricing.
- 03Detailed segment figures, rebate pressure and guidance will matter more than the headline beat for anyone tracking access.
From the source
Read at qz.comEli Lilly Q1 2026 earnings: Mounjaro, Zepbound drive strong results
